nVerses Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

nVerses Capital’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,800	Closed	-$62.2K	–	982
2024 Q2	$62.2K	Buy	+9,800	New	+$62.2K	0.04%	557

Other funds holding AMRX

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

nVerses Capital's AMRX Position: Q3 2024 in Review

nVerses Capital sold out of Amneal Pharmaceuticals (AMRX) in Q3 2024, closing a stake of 9,800 shares — an estimated $62.2K sold.

nVerses Capital first reported a position in AMRX in Q2 2024 and held it in 1 quarter. The position peaked at $62.2K in Q2 2024. 182 funds tracked by Wall St. Rank hold AMRX as of Q3 2024.

nVerses Capital reported no remaining Amneal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 9,800 Amneal Pharmaceuticals shares in Q3 2024, an estimated $62.2K.
nVerses Capital first reported a position in Amneal Pharmaceuticals in Q2 2024 and held it in 1 quarter.
nVerses Capital's Amneal Pharmaceuticals position peaked at $62.2K in Q2 2024.
182 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.